Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma
Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma: Study Protocol of a Randomized, Non-inferior Clinical Trial
This randomized, non-inferiority clinical trial aims to evaluate whether non-resection of needle biopsy tract is non-inferior to routine biopsy tract resection in terms of local recurrence in patients with primary extremity musculoskeletal sarcoma undergoing en-bloc surgical treatment.
Biopsy tract resection is traditionally recommended to reduce the risk of tumor seeding; however, its benefit in reducing recurrence has not been definitively demonstrated, particularly when core needle biopsy is widely used. Also, avoiding biopsy tract resection may preserve uninvolved tissue without compromising oncologic safety.
The primary objective of this study is to compare local recurrence rates between patients who undergo biopsy tract resection and those who do not. Secondary objectives include comparisons of surgical complications, functional outcomes, overall survival, and progression-free survival.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Nong Lin, MD
- 電話番号:13958195545
- メール:linnong@zju.edu.cn
研究場所
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国
- Hangzhou Third People's Hospital
-
コンタクト:
- Yefeng Xu
- 電話番号:15068710437
- メール:2173799040@qq.com
-
Hangzhou、Zhejiang、中国、311200
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
コンタクト:
- Keyi Wang, MS
- 電話番号:17398046579
- メール:wky82630965@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Histologically confirmed diagnosis of primary bone or soft tissue sarcoma of the extremities (or highly suspected sarcoma);
- Candidate for limb-sparing surgery and capable of en-bloc resection;
- Age ≥ 5 years;
- ECOG performance status 0-2;
- Able to understand and sign informed consent.
Exclusion Criteria:
- Presence of distant metastasis (e.g., lung, bone, or other sites) or unresectable skip lesions;
- Patients deemed, based on preoperative multidisciplinary team (MDT) evaluation, unlikely to achieve adequate surgical margins and therefore only eligible for debulking or palliative surgery;
- Patients with inconclusive needle biopsy results requiring open biopsy for definitive diagnosis;
- Patients requiring amputation;
- Patients who have received prior treatment for the tumor at non-participating centers;
- Patients with an expected survival of less than 2 years;
- Patients in whom the biopsy tract completely lies within the planned tumor resection field;
- Patients who refuse to provide written informed consent.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:tract resection group
|
Surgeons will perform standard en-bloc tumor resection according to oncologic principles. In the biopsy tract resection group, complete biopsy tract excision is defined as en-bloc removal of the entire needle biopsy pathway, including: Skin entry site: the original puncture site on the skin surface Subcutaneous and soft tissue tract: all intervening tissues traversed by the biopsy needle Deep tract structures: any muscle, fascia, periosteum, or bone structures penetrated by the needle Intratumoral component: the terminal segment of the needle pathway within the tumor All components of the biopsy tract must be removed together with the tumor specimen. |
|
アクティブコンパレータ:tract non-section group
|
Surgeons will perform standard en bloc tumor resection in accordance with oncologic principles. In the non-resection group, the needle biopsy tract will not be intentionally excised. The biopsy tract, including the skin entry site and intervening soft tissue pathway, will be preserved unless it lies within the planned tumor resection field. If any portion of the biopsy tract is located within the standard oncologic resection field required to achieve negative margins, it will be removed as part of the tumor specimen; however, no additional resection will be performed specifically to excise the biopsy tract. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cumulative incidence of local recurrence at 2 years
時間枠:From the date of surgery to the date of first documented local recurrence, death, or last follow-up, assessed up to 24 months after surgery.
|
Local recurrence is defined as radiologically or pathologically confirmed recurrence of sarcoma at or adjacent to the primary surgical site after definitive tumor resection.
The cumulative incidence of local recurrence will be estimated with death treated as a competing event.
|
From the date of surgery to the date of first documented local recurrence, death, or last follow-up, assessed up to 24 months after surgery.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Musculoskeletal Tumor Society score
時間枠:recorded at baseline and at 3, 6, 9, 12, 15, 18, 21, and 24 months after surgery.
|
MSTS assesses 6 aspects of a patient's quality including pain, function, emotional, supports, walking and gait with regard to their treatment.
higher score.
The score ranges from 0% (worst function) to 100% (best function).
It is a repeated continuous outcome.
|
recorded at baseline and at 3, 6, 9, 12, 15, 18, 21, and 24 months after surgery.
|
|
Henderson failure mode
時間枠:From surgery to 24 months, assessed every 3 months
|
Henderson failure mode defined as : soft-tissue failure (Type 1), aseptic loosening (Type 2), structural failure (Type 3), infection (Type 4), and tumor progression (Type 5).
|
From surgery to 24 months, assessed every 3 months
|
|
The Patient and Observer Scar Assessment Scale
時間枠:From surgery to 24 months, assessed every 3 months
|
The Patient and Observer Scar Assessment Scale (POSAS) questionnare is used to evaluate scar quality from both the patient's and the observer's perspectives.
Each scale consists of six items, with each item scored from 1 (normal skin) to 10 (worst imaginable scar).
Total scores range from 6 to 60, with lower scores indicating better quality.
|
From surgery to 24 months, assessed every 3 months
|
|
Soft tissue reconstruction
時間枠:perioperative period
|
Soft tissue reconstruction will be recorded as whether the patient required additional soft tissue reconstruction procedures (e.g., skin grafting) during surgery.
|
perioperative period
|
|
Total surgical duration
時間枠:During the operative procedure
|
The time elapsed from the first incision to the completion of wound closure, measured in minutes.
|
During the operative procedure
|
|
Biopsy diagnostic accuracy
時間枠:perioperative period
|
Diagnostic accuracy was defined as the percentage of participants whose percutaneous biopsy results are concordant with the final histopathological diagnosis from the surgical specimen.
This is a binary outcome.
|
perioperative period
|
|
Metastasis free survival (MFS)
時間枠:From surgery to 24 months, assessed every 6 months
|
Metastasis-free survival is defined as the time from definitive surgery to the first radiologically confirmed distant metastasis (e.g., lung, bone, or other organs).
Metastasis will be assessed using scheduled chest CT scans and other imaging as clinically indicated.
Participants without metastasis will be censored at their last follow-up visit.
|
From surgery to 24 months, assessed every 6 months
|
|
The Toronto Extremity Salvage Score
時間枠:From surgery to 24 months, assessed every 3 months
|
The Toronto Extremity Salvage Score (TESS) is a patient-reported outcome measure (PROM) specifically designed to evaluate the physical function of individuals who have undergone limb-salvage surgery for bone or soft-tissue sarcomas.The raw score is converted into a percentage ranging from 0 to 100.
Higher score indicates better function.
|
From surgery to 24 months, assessed every 3 months
|
|
Overall survival (OS)
時間枠:From surgery to 24 months, assessed every 3 months
|
Overall survival is defined as the time from definitive surgery to death from any cause.
Participants alive at last follow-up will be censored.
Survival status will be assessed at each scheduled visit.
|
From surgery to 24 months, assessed every 3 months
|
|
Need for re-biopsy
時間枠:preoperative period
|
Number of participants requiring more than one biopsy procedure to obtain a definitive diagnostic result.
|
preoperative period
|
|
Request for external pathology consultation
時間枠:perioperative period
|
Number of participants for whom a second opinion from an external pathology department was sought to confirm the primary diagnosis.
|
perioperative period
|
|
intraoperative blood loss
時間枠:During the surgical procedure
|
Total volume of blood lost during the surgical procedure, measured in milliliters (mL).
|
During the surgical procedure
|
|
length of hospital stay
時間枠:perioperative period
|
The total number of days from the date of admission to the date of hospital discharge.
This is a continuous outcome
|
perioperative period
|
|
Major wound complications
時間枠:Assessed from the date of surgery to 120 days after surgery.
|
Major wound complication was defined according to the O' sullivian et al (the Lancet, 2002). They are defined as a secondary operation under general or regional anaesthesia for wound repair (debridement, operative drainage, and secondary wound closure including rotationplasty, free flaps, or skin grafts),or wound management without secondary operation. Wound management included an invasive procedure without general or regional anaesthesia (mainly aspiration of seroma), readmission for wound care such as intravenous antibiotics, or persistent deep packing for 120 days or longer. It will be recorded as binary outcome |
Assessed from the date of surgery to 120 days after surgery.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- LN_Biopsy_2025
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。